Home
LEXX
LEXX News

Latest Lexaria Bioscience Corp. (LEXX) News on October 7, 2025

LEXX: Biodistribution Study Results

Zacks Small Cap Research

5 days ago

LEXX: Biodistribution Study Results

MT Newswires

3 months ago

Lexaria Bioscience Secures 2 Patents in Australia, Japan

LEXX: GLP-1-H25-5 Study Complete

Zacks Small Cap Research

4 months ago

LEXX: GLP-1-H25-5 Study Complete

Lexaria Bioscience announces completion of GLP-1-H25-5 study

TipRanks

4 months ago

Lexaria Bioscience announces completion of GLP-1-H25-5 study

ACCESS Newswire

4 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

ACCESS Newswire

4 months ago

Lexaria Attending BIO International Convention

ACCESS Newswire

5 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

NewMediaWire

5 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

NewMediaWire

5 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

LEXX: Second Quarter Results

Zacks Small Cap Research

5 months ago

LEXX: Second Quarter Results

ACCESS Newswire

5 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

Simply Wall St.

6 months ago

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

ACCESS Newswire

6 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire

6 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

ACCESS Newswire

7 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

ACCESS Newswire

7 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

ACCESS Newswire

7 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

ACCESS Newswire

8 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

ACCESS Newswire

8 months ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

ACCESS Newswire

8 months ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

ACCESS Newswire

8 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire

8 months ago

Lexaria Releases Annual Letter from the CEO

LEXX: IRB Approval Clears Way for GLP-1 Study #5

Zacks Small Cap Research

8 months ago

LEXX: IRB Approval Clears Way for GLP-1 Study #5

MT Newswires

9 months ago

Lexaria Bioscience Receives Ethics Board Approval for Oral Liraglutide Pilot Study

ACCESS Newswire

9 months ago

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

MT Newswires

9 months ago

Lexaria Bioscience Says Oral DehydraTECH-Tirzepatide Causes Fewer Adverse Effects

ACCESS Newswire

9 months ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

9 months ago

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Lexaria's Registered GLP-1 Study #4 Begins Dosing

ACCESSWIRE

10 months ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

ACCESSWIRE

10 months ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

ACCESSWIRE

10 months ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide

TipRanks

10 months ago

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

ACCESSWIRE

10 months ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

LEXX: Phase I Start Imminent

Zacks Small Cap Research

10 months ago

LEXX: Phase I Start Imminent

Newsfile

10 months ago

BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

10 months ago

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

ACCESSWIRE

10 months ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ACCESSWIRE

10 months ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

ACCESSWIRE

a year ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

ACCESSWIRE

a year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

MT Newswires

a year ago

Lexaria Bioscience Gets Ethics Board Approval to Begin Dosing in Phase 1b Diabetes, Weight Loss Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

ACCESSWIRE

a year ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

ACCESSWIRE

a year ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

ACCESSWIRE

a year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study

ACCESSWIRE

a year ago

Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth

MT Newswires

a year ago

Lexaria Bioscience Expects to Raise $5 Million in Registered Direct Offering

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

a year ago

Lexaria Bioscience Launches Human Study of DehydraTECH-Processed Tirzepatide

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

ACCESSWIRE

a year ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria Updates Current GLP-1 Market

ACCESSWIRE

a year ago

Lexaria Updates Current GLP-1 Market

MT Newswires

a year ago

Lexaria Bioscience Names Michael Shankman CFO

Lexaria Appoints Michael Shankman as Chief Financial Officer

ACCESSWIRE

a year ago

Lexaria Appoints Michael Shankman as Chief Financial Officer

MT Newswires

a year ago

Lexaria Bioscience Receives Approval From Independent Review Board for Pilot Study of Tirzepatide

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

ACCESSWIRE

a year ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Zacks Small Cap Research

a year ago

LEXX: Changing Gears: Christopher Takes Over as CEO

MT Newswires

a year ago

Lexaria Bioscience Taps InVivo Therapeutics CFO Richard Christopher As New CEO

Lexaria Releases Strategic Letter from the Outgoing CEO

ACCESSWIRE

a year ago

Lexaria Releases Strategic Letter from the Outgoing CEO

Lexaria Welcomes Industry Veteran as New CEO

ACCESSWIRE

a year ago

Lexaria Welcomes Industry Veteran as New CEO

ACCESSWIRE

a year ago

Lexaria Enters a Material Transfer Agreement for DehydraTECH Research

MT Newswires

a year ago

Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events

ACCESSWIRE

a year ago

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

First Results from Lexaria's Second GLP-1 Human Pilot Study

MT Newswires

a year ago

Lexaria Bioscience Says Liraglutide 'Outperforming' Semaglutide in Animal Weight Loss Study

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

ACCESSWIRE

a year ago

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

MT Newswires

a year ago

Lexaria Bioscience Reports Blood Sugar Reductions in Ongoing Diabetes Study; Shares Fall

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

ACCESSWIRE

a year ago

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Results from Lexaria's Molecular Characterization Study

ACCESSWIRE

a year ago

Positive Results from Lexaria's Molecular Characterization Study

LEXX: GLP-1 Agonist Program Updates

Zacks Small Cap Research

a year ago

LEXX: GLP-1 Agonist Program Updates

Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

ACCESSWIRE

a year ago

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Lexaria Preparing For Strategic Growth

ACCESSWIRE

a year ago

Lexaria Preparing For Strategic Growth

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

MT Newswires

a year ago

Lexaria Bioscience Secures New Antiviral Drug Delivery, Epilepsy Patents

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

ACCESSWIRE

a year ago

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

MT Newswires

a year ago

Lexaria Bioscience Hires Contract Research Organization For 12-week Study

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

ACCESSWIRE

a year ago

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

MT Newswires

a year ago

Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study

Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study

Lexaria Awards Contract For Third GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Lexaria Awards Contract For Third GLP-1 Human Pilot Study

MT Newswires

a year ago

Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise

Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

ACCESSWIRE

a year ago

Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study

ACCESSWIRE

a year ago

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

ACCESSWIRE

a year ago

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

ACCESSWIRE

a year ago

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

LEXX: Begin with the End in Mind

Zacks Small Cap Research

a year ago

LEXX: Begin with the End in Mind

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

ACCESSWIRE

a year ago

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Lexaria Awarded New Patents

ACCESSWIRE

2 years ago

Lexaria Awarded New Patents

Newsfile

2 years ago

Lexaria to Present at The LD Micro Invitational XIV

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

ACCESSWIRE

2 years ago

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

ACCESSWIRE

2 years ago

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

ACCESSWIRE

2 years ago

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

ACCESSWIRE

2 years ago

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

ACCESSWIRE

2 years ago

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year

Simply Wall St.

2 years ago

This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

2 years ago

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

2 years ago

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Share on Social Networks: